Case Overview: An Illinois appellate court has reversed a multi-million-dollar verdict against baby formula maker Mead Johnson, ruling that the learned intermediary doctrine shields the company from failure-to-warn claims when its preterm formula is administered in a hospital NICU under physician supervision.

Consumers Affected: Families of premature infants who received cow milk-based preterm formula in neonatal intensive care units

Court: Illinois Appellate Court, Fifth District

Latest Development: Appellate court reversed the trial court verdict and applied the learned intermediary doctrine to hospital-administered infant formula for the first time

Illinois Court Overturns Multi-Million Dollar Baby Formula Verdict in Landmark Ruling

An Illinois appellate court has reversed a multi-million-dollar jury verdict against infant formula manufacturer Mead Johnson, applying a legal doctrine traditionally reserved for prescription drugs to cow milk-based preterm formula administered in a hospital neonatal intensive care unit.

The ruling in Watson v. Mead Johnson & Company, LLC represents what legal analysts are calling a first-of-its-kind decision in the country.

What Happened

According to analysis published by the Drug & Device Law Blog, the Illinois Appellate Court, Fifth District issued its ruling on June 12, 2026, reversing the trial court's verdict and holding that the learned intermediary doctrine applies to infant formula used exclusively in a hospital setting under physician oversight.

The decision in 2026 IL App (5th) 240936 is believed to be the first ruling by any appellate court in the United States to extend the learned intermediary doctrine to a product not formally classified as a prescription drug by the FDA.

Background: What the Case Was About

The litigation centered on cow milk-based preterm formula administered to premature newborns in a neonatal intensive care unit. The plaintiffs alleged that Mead Johnson failed to adequately warn of risks associated with its formula when fed to premature infants.

At the heart of the case was the question of who bears responsibility for warning consumers — or in this case, the families of vulnerable patients — about a product's potential risks.

The Learned Intermediary Doctrine, Explained

The learned intermediary doctrine is a legal principle that generally allows drug and device manufacturers to satisfy their duty to warn by providing adequate information to prescribing physicians rather than directly to patients. Under this framework, the physician serves as the "learned intermediary" between the manufacturer and the patient.

The doctrine has historically applied to prescription medications — products that, by law, require a physician's authorization before a patient can obtain them. Baby formula, including the preterm varieties used in NICUs, carries no such formal prescription requirement.

However, the Illinois appellate court found that the practical circumstances surrounding how Mead Johnson's preterm formula was used mattered more than the regulatory label. According to the ruling, the formula was administered through a feeding tube, ordered by neonatologists, and selected only after individualized clinical review of each infant's gestational age, birth weight, comorbidities, and the available feeding alternatives — a process that closely mirrors how prescription drugs are managed.

The court determined that the formal absence of an FDA prescription requirement did not preclude the doctrine's application under these circumstances.

What This Ruling Means for Plaintiffs

The reversal is significant for families pursuing similar claims. By applying the learned intermediary doctrine, the court effectively shifted the failure-to-warn analysis away from whether Mead Johnson adequately warned parents, and toward whether it adequately warned the physicians who made the feeding decisions.

For the plaintiffs in Watson, this distinction was outcome-determinative — the jury's multi-million-dollar verdict was reversed.

The ruling may have broader implications for ongoing and future litigation involving specialty medical nutrition products administered in clinical settings, particularly as necrotizing enterocolitis (NEC) lawsuits against infant formula manufacturers continue to proceed in courts across the country.

What's Next

The Watson decision establishes precedent in Illinois intermediate appellate courts, though it could be subject to further review. Its influence on litigation in other jurisdictions will likely depend on how courts in those states have interpreted the boundaries of the learned intermediary doctrine.

Defense attorneys in pending NEC and preterm formula cases are expected to cite the ruling in support of similar arguments. How plaintiffs' counsel respond — and whether courts in other circuits follow Illinois's lead — will shape how this litigation develops in the months ahead.

Case: Watson v. Mead Johnson & Company, LLC

Citation: 2026 IL App (5th) 240936; 2026 WL 1706992

Court: Illinois Appellate Court, Fifth District

Decision Date: June 12, 2026

Status: Trial court verdict reversed; learned intermediary doctrine applied

This article is for informational purposes only and does not constitute legal or medical advice. Consult a qualified attorney if you have questions about a potential legal claim.

Were you or your child affected by complications related to preterm infant formula in a NICU setting? Claims may still be open in ongoing litigation — check eligibility below.